Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.000
-0.090 (-8.26%)
Nov 4, 2024, 4:00 PM EST - Market closed
Biofrontera Revenue
Biofrontera had revenue of $7.84M in the quarter ending June 30, 2024, with 34.05% growth. This brings the company's revenue in the last twelve months to $35.24M, up 21.33% year-over-year. In the year 2023, Biofrontera had annual revenue of $34.07M with 18.82% growth.
Revenue (ttm)
$35.24M
Revenue Growth
+21.33%
P/S Ratio
0.09
Revenue / Employee
$414,600
Employees
85
Market Cap
5.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
Dec 31, 2019 | 26.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sunshine Biopharma | 30.48M |
Kindly MD | 3.10M |
Xenetic Biosciences | 2.52M |
Mainz Biomed | 917.20K |
Eterna Therapeutics | 162.00K |
BFRI News
- 3 days ago - Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Accesswire
- 4 days ago - Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 21 days ago - Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 4 weeks ago - FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - GlobeNewsWire
- 5 weeks ago - Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - Accesswire
- 2 months ago - Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024 - Accesswire